Anti-psychotic Drug Prescribing Patterns Within Specialist Adult ID Services in England and Wales (APHID)

University of Plymouth

Status: Enrolling

Conditions: Intellectual Disability

Study type: Observational

Funder types: Other

Identifiers

NCT06238089

TRUST/VC/AC/SG/6328-9580 (Other Grant/Funding Number)

331470 (Other Identifier)

4548

Details and patient eligibility

About

The overall aim of this observational study is to establish the anti-psychotic prescribing patterns across specialist intellectual disability (ID) services in England and Wales by collecting cross-sectional retrospective data at 7 annual time-points (1st July) from 2017 to 2023.

Full description

Feasibility protocol objectives:

1. Is it feasible to identify People with Intellectual Disabilities (PwID) who have been prescribed 2 or more anti-psychotic medications over 7 years retrospectively.

2. It is possible to obtain a complete data set for each patient identified and therefore be able to explore the prescribing patterns across the eight sites.

3. Is it feasible to quantify anti-psychotic treatment (APT) prescribing in PwID as chlorpromazine equivalent dose values across different healthcare Trusts in England and Wales.

   Main objectives:

4. To explore yearly and overall prescribing patterns among PwID (with or without mental-health reasons (psychiatric co-morbidities)) in receipt of ≥2 forms of anti-psychotic treatment (multiple) over time?

5. How has multiple anti-psychotic treatment prescribing changed between 2017 and 2023 using chlorpromazine equivalent dose values, in PwID with mental health and no mental health indications?

6. What has been the impact of the COVID-19 pandemic (and corresponding lockdown restrictions in England and Wales) on multiple anti-psychotic treatment prescribing among PwID?

7. Can the NHS England Statistical Process Control tool (SPC) be utilised to track yearly anti-psychotic treatment prescribing among PwID receiving multiple forms of anti-psychotic treatment, and monitor variation between services (sites) and patient groups (e.g. psychiatric co-morbidities; challenging behaviour).

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient had psychiatric review by specialist adult ID services in the last year (e.g. for a patient to be included at 1st June 2017, data to be recorded from the most recent psychiatric review within the period between 1st January 2017 - 31st December 2017).
• Patient has a diagnosis of ID
• Patient under the care of specialist adult ID services
• Patient on >2 anti-psychotic treatments (oral and IM injectable (depots))

Exclusion criteria

• Patients treated with Clozapine
• Under the age of 18 years

Trial design

600 participants in 7 patient groups

Eligible patients who have had a psychiatric review by specialist adult ID services in 2017.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting intra-muscular (IM) injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2017.

Eligible patients who have had a psychiatric review by specialist adult ID services in 2018.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2018.

Eligible patients who have had a psychiatric review by specialist adult ID services in 2019.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2019.

Eligible patients who have had a psychiatric review by specialist adult ID services in 2020.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2020.

Eligible patients who have had a psychiatric review by specialist adult ID services in 2021.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2021.

Eligible patients who have had a psychiatric review by specialist adult ID services in 2022.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2022.

Eligible patients who have had a psychiatric review by specialist adult ID services in 2023.

Description:

Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2023.